Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Associations of corticosteroid therapy with weight change and appetite in patients with advanced pancreatic cancer - a post hoc analysis from the MISTRAL trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Confounding by indication in corticosteroid use and nutritional outcomes in advanced pancreatic cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLoss of appetite and weight loss are major concerns in patients with pancreatic cancer. The aim of this study was to evaluate the associations of corticosteroid therapy with weight change and appetite in the long term, in patients with advanced pancreatic cancer.
methodsThis was a post hoc analysis of the previously performed randomized, controlled MISTRAL trial in patients with advanced pancreatic cancer. Data on weight and appetite at baseline and after approximately 1, 2, 3 and 4 months were used. The association between corticosteroid exposure and weight change was calculated using mixed linear regression, models adjusted for sex, age, randomization arm and performance status. Appetite was analyzed comparing those without and with corticosteroids during 3 days before appetite assessment.
resultsTwo hundred forty-four patients (121 women) were included. Patients who received corticosteroid therapy at any time during the 4 months had less appetite (p < 0.001), lower performance status (p < 0.001) and lower BMI (p < 0.05) compared to those not receiving corticosteroids. Patients receiving corticosteroids had a larger weight loss of on average 1.48% during a month of follow-up compared to those not receiving corticosteroids (β - 1.48, 95% CI = - 2.11 to - 0.84). Patients exposed to corticosteroids reported poorer appetite at every time point than those not exposed.
conclusionIn long-term follow-up, corticosteroid treatment was associated with greater weight loss and poorer appetite among patients with advanced pancreatic cancer. These findings may partly be explained by a higher symptom burden among patients receiving corticosteroids. Future prospective trials are warranted to clarify the effect of long-term corticosteroid treatment on weight and appetite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.